GlassScriptPhysician profile
Jorge Cheirif
NPI 1598703803
$92,336.59
in general payments reported to CMS, 2019-2025
41 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $16K · 2021: $11K · 2022: $13K · 2023: $9,157 · 2024: $1,840 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,100 · Food and Beverage: $4,130 · Education: $201 · Debt Forgiveness: $55.76 · Travel and Lodging: $16.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,100.00 |
| Food and Beverage | $4,130.35 |
| Education | $200.68 |
| Debt Forgiveness | $55.76 |
| Travel and Lodging | $16.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $46,073.88 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $16,054.81 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13,089.89 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $9,757.00 | 2019-2023 | Farxiga, Brilinta |
| Regeneron Healthcare Solutions, INC. | $1,054.43 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $737.12 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $643.67 | 2021-2025 | Verquvo, Capvaxive, Winrevair |
| Novartis Pharmaceuticals Corporation | $587.82 | 2019-2025 | |
| Pfizer INC. | $403.73 | 2019-2025 | |
| Boston Scientific Corporation | $387.37 | 2019-2025 | Watchman Flx |
| Heartflow, INC. | $364.09 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $358.67 | 2022-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.85 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $295.38 | 2021-2025 | Nexletol |
| Abbott Laboratories | $281.93 | 2020-2025 | Jot Dx |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $280.50 | 2021-2025 | Watchpatone |
| Medtronic, INC. | $243.16 | 2021-2025 | Symplicity G3, Linq II |
| Amgen INC. | $151.12 | 2019-2025 | Repatha, Repatha |
| Abiomed | $148.56 | 2024 | Impella |
| Lexicon Pharmaceuticals, INC. | $133.05 | 2024 | |
| Scpharmaceuticals INC. | $111.16 | 2023-2025 | |
| Novo Nordisk INC | $108.66 | 2023-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $79.23 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $65.54 | 2021-2022 | |
| Baxter Healthcare | $55.76 | 2023 | |
| Azurity Pharmaceuticals, INC. | $54.72 | 2024-2025 | Edarbi |
| Amarin Pharma, INC. | $50.16 | 2019-2021 | |
| Philips North America LLC | $49.12 | 2020-2023 | |
| Gilead Sciences, INC. | $45.47 | 2019 | |
| Inspire Medical Systems, INC. | $42.57 | 2024-2025 | Inspire |
| Vivaquant INC, Dba Rhythm Express | $39.40 | 2024 | Rhythm Express |
| Cvrx, INC. | $37.80 | 2024 | Barostim Neo System |
| Lilly USA, LLC | $35.30 | 2024-2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $34.34 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $32.22 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $28.00 | 2023 | Injectafer |
| Medicomp INC | $22.49 | 2023 | Telepatch Cardiac Monitor |
| Bardy Diagnostics, INC. | $21.00 | 2019 | |
| Siemens Medical Solutions USA, INC. | $20.41 | 2019 | |
| United Therapeutics Corporation | $16.43 | 2019 | |
| Portola Pharmaceuticals, LLC | $15.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Cheirif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.